Additionally, it has been shown that ARID1A deficiency may lead to a synthetic lethal therapy response to Ataxia telangiectasia and Rad3 related (ATR) inhibitors in several tumor entities [34]. The gene discussed is ARID1A; the disease is neoplasm.